Payment overview · 2025
General Payments
$1,588.07
73 reported records · 16 companies
Healthcare provider profile · identity verified
Mario A Rodriguez, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · RIO GRANDE CITY, TX · NPI 1528086006
Verified facts
What the public records show
CMS Open Payments records show Mario A Rodriguez, M.D. received $1,588.07 in general payments during 2025 across 73 reported records.
ABBVIE INC. accounted for 28.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Mounjaro, Otezla, Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 288 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 387 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 467 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 270 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 614 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 255 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $458.92 | 28.9% | 23 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $316.29 | 19.9% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $293.52 | 18.5% | 14 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $154.89 | 9.8% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $71.68 | 4.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $64.54 | 4.1% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $43.79 | 2.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $28.12 | 1.8% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.40 | 1.5% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $22.26 | 1.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.80 | 1.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.93 | 1.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.44 | 1.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.02 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.50 | 1.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.97 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,588.07 | 73 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $370.28 | 18 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $316.29 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $146.85 | 6 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $140.13 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $115.62 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $88.64 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $78.28 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $74.93 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $64.54 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $64.54 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $43.79 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $41.34 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.34 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $38.50 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $30.34 | 2 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $28.12 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.93 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 387 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 270 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 614 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 255 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
288 | 95 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
22 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
387 | 84 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
467 | 103 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
270 | 69 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
159 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
614 | 125 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
255 | 55 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
206 | 52 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1502 | 463 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1466 | 458 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1048 | 320 |
| Metformin Hcl | Metformin Hcl | 1042 | 298 |
| Alprazolam | Alprazolam | 1002 | 168 |
| Metoprolol Succinate | Metoprolol Succinate | 903 | 269 |
| Amlodipine Besylate | Amlodipine Besylate | 878 | 256 |
| Memantine Hcl | Memantine Hcl | 793 | 178 |
| Levothyroxine Sodium | Levothyroxine Sodium | 785 | 210 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 780 | 225 |
| Tamsulosin Hcl | Tamsulosin Hcl | 678 | 205 |
| Losartan Potassium | Losartan Potassium | 658 | 194 |
| Gabapentin | Gabapentin | 633 | 191 |
| Ozempic | Semaglutide | 614 | 125 |
| Donepezil Hcl | Donepezil Hcl | 596 | 153 |
| Montelukast Sodium | Montelukast Sodium | 557 | 176 |
| Tramadol Hcl | Tramadol Hcl | 539 | 125 |
| Irbesartan | Irbesartan | 530 | 159 |
| Simvastatin | Simvastatin | 486 | 126 |
| Sertraline Hcl | Sertraline Hcl | 483 | 121 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 468 | 126 |
| Jardiance | Empagliflozin | 467 | 103 |
| Lisinopril | Lisinopril | 463 | 147 |
| Omeprazole | Omeprazole | 430 | 130 |
| Alendronate Sodium | Alendronate Sodium | 420 | 132 |
| Farxiga | Dapagliflozin Propanediol | 387 | 84 |
| Clopidogrel | Clopidogrel Bisulfate | 372 | 104 |
| Glipizide | Glipizide | 366 | 108 |
| Meloxicam | Meloxicam | 365 | 136 |
| Furosemide | Furosemide | 359 | 102 |
| Escitalopram Oxalate | Escitalopram Oxalate | 357 | 117 |
| Celecoxib | Celecoxib | 342 | 154 |
| Linzess | Linaclotide | 288 | 95 |
| Diclofenac Sodium | Diclofenac Sodium | 278 | 113 |
| Meclizine Hcl | Meclizine Hcl | 270 | 84 |
| Mounjaro | Tirzepatide | 270 | 69 |
| Zolpidem Tartrate | Zolpidem Tartrate | 264 | 63 |
| Glipizide Er | Glipizide | 260 | 109 |
| Metoprolol Tartrate | Metoprolol Tartrate | 255 | 66 |
| Rybelsus | Semaglutide | 255 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 247 | 80 |
| Clonazepam | Clonazepam | 236 | 41 |
| Pregabalin | Pregabalin | 234 | 59 |
| Myrbetriq | Mirabegron | 229 | 60 |
| Januvia | Sitagliptin Phosphate | 220 | 56 |
| Tradjenta | Linagliptin | 218 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 216 | 65 |
| Trazodone Hcl | Trazodone Hcl | 215 | 54 |
| Carvedilol | Carvedilol | 213 | 77 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 212 | 58 |
| Fenofibrate | Fenofibrate Nanocrystallized | 212 | 63 |
| Eliquis | Apixaban | 206 | 52 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 177 | 52 |
| Fluoxetine Hcl | Fluoxetine Hcl | 170 | 41 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 168 | 54 |
| Ibuprofen | Ibuprofen | 168 | 63 |
| Fluticasone Propionate | Fluticasone Propionate | 167 | 60 |
| Potassium Chloride | Potassium Chloride | 159 | 41 |
| Trulicity | Dulaglutide | 159 | 35 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 153 | 46 |
| Famotidine | Famotidine | 150 | 48 |
| Dutasteride | Dutasteride | 140 | 49 |
| Ezetimibe | Ezetimibe | 140 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 139 | 75 |
| Allopurinol | Allopurinol | 138 | 51 |
| Lorazepam | Lorazepam | 138 | 21 |
| Tresiba Flextouch U-100 | Insulin Degludec | 136 | 40 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 130 | 115 |
| Cilostazol | Cilostazol | 120 | 29 |
| Nifedipine Er | Nifedipine | 120 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 117 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 31 |
| Baclofen | Baclofen | 111 | 47 |
| Spironolactone | Spironolactone | 107 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 101 | 43 |
| Dexlansoprazole Dr | Dexlansoprazole | 97 | 21 |
| Levofloxacin | Levofloxacin | 96 | 88 |
| Dicyclomine Hcl | Dicyclomine Hcl | 94 | 29 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 92 | 27 |
| Xarelto | Rivaroxaban | 90 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 88 | 80 |
| Azithromycin | Azithromycin | 87 | 79 |
| Entresto | Sacubitril/Valsartan | 82 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 81 | 28 |
| Mirtazapine | Mirtazapine | 81 | 15 |
| Clonidine Hcl | Clonidine Hcl | 80 | 23 |
| Nitroglycerin | Nitroglycerin | 79 | 27 |
| Sucralfate | Sucralfate | 78 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 26 |
| Levetiracetam | Levetiracetam | 75 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 70 | 25 |
| Single Use Swab | Alcohol Antiseptic Pads | 70 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 26 |
| Finasteride | Finasteride | 69 | 21 |
| Lovastatin | Lovastatin | 69 | 21 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 69 | 16 |
| Vascepa | Icosapent Ethyl | 69 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 68 | 35 |
| Alcohol Pads | Alcohol Antiseptic Pads | 67 | 27 |
| Gemfibrozil | Gemfibrozil | 66 | 17 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 66 | 17 |
| Midodrine Hcl | Midodrine Hcl | 66 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 34 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 65 | 22 |
| Tresiba Flextouch U-200 | Insulin Degludec | 64 | 16 |
| Primidone | Primidone | 63 | 20 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 62 | 31 |
| Enalapril Maleate | Enalapril Maleate | 62 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 60 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 17 |
| Lactulose | Lactulose | 58 | 16 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 57 | 26 |
| Atenolol | Atenolol | 57 | 16 |
| Bumetanide | Bumetanide | 57 | 13 |
| Vraylar | Cariprazine Hcl | 57 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 17 |
| Metformin Hcl Er | Metformin Hcl | 54 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 53 | 18 |
| Glyxambi | Empagliflozin/Linagliptin | 53 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 53 | 16 |
| Olanzapine | Olanzapine | 53 | suppressed |
| Fenofibrate | Fenofibrate | 52 | 13 |
| Glimepiride | Glimepiride | 51 | 14 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 49 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 46 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 45 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 44 | 12 |
| Prednisone | Prednisone | 44 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 42 | 11 |
| Telmisartan | Telmisartan | 42 | 13 |
| Ranolazine Er | Ranolazine | 41 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | 17 |
| Sulfasalazine | Sulfasalazine | 40 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 39 | 12 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 39 | 13 |
| Lidocaine | Lidocaine | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | 12 |
| Naproxen | Naproxen | 36 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 35 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | 11 |
| Jentadueto | Linagliptin/Metformin Hcl | 34 | suppressed |
| Brilinta | Ticagrelor | 33 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 33 | 11 |
| Lubiprostone | Lubiprostone | 32 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | suppressed |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Latanoprost | Latanoprost | 31 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 17 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 28 | 23 |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Cefdinir | Cefdinir | 27 | 25 |
| Nitroglycerin Patch | Nitroglycerin | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | 11 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 26 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | 12 |
| Cephalexin | Cephalexin | 25 | 21 |
| Colchicine | Colchicine | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 17 |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 24 | suppressed |
| Sotalol | Sotalol Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Prolia | Denosumab | 22 | 16 |
| Clonidine | Clonidine | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Temazepam | Temazepam | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | 20 |
| Bydureon Bcise | Exenatide Microspheres | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 20 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 20 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Constulose | Lactulose | 19 | 14 |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Levemir | Insulin Detemir | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Procto-Med Hc | Hydrocortisone | 18 | 12 |
| Rivastigmine | Rivastigmine | 18 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | 11 |
| Nystatin | Nystatin | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 13 |
| Metolazone | Metolazone | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 15 | 13 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 15 | suppressed |
| Novolin R | Insulin Regular, Human | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Sevelamer Carbonate | Sevelamer Carbonate | 14 | suppressed |
| Trulance | Plecanatide | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Tresiba | Insulin Degludec | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,588.07 · 73 records | ABBVIE INC. | AIRSUPRA, Auvelity, BREZTRI, CAPVAXIVE, CARDIOMEMS, Cologuard Collection Kit, EVENITY, FARXIGA, FUROSCIX, GARDASIL 9, GEMTESA, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VERQUVO, VRAYLAR, ZEPBOUND, ZORYVE | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error